Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis

NCT00484302 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2011-01-25

No results posted yet for this study

Summary

The purpose of the trial is to investigate the effect of specialized treatment of cannabis abuse among young people with psychosis. The specialized treatment consists of manualized individual treatment and group therapy. It will be compared with the standard treatment, which consists of non-specialized, non-manualized treatment. 140 patients will be randomised to one of the two treatments, and the investigator(s) will be blinded to the treatment received.

Conditions

Interventions

BEHAVIORAL

Cognitive behavioral therapy with motivational interviewing

Individual and group therapy, education of family and case-manager.

BEHAVIORAL

Non-manualized standard treatment

Treatment by case-manager

Sponsors & Collaborators

  • Copenhagen Trial Unit, Center for Clinical Intervention Research

    collaborator OTHER
  • Sygekassernes Helsefond

    collaborator OTHER
  • Københavns Kommune

    collaborator OTHER
  • Lundbeck Foundation

    collaborator OTHER
  • Psychiatric Center Copenhagen

    collaborator UNKNOWN
  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Merete Nordentoft, MD, PhD, MPH · Psychiatric Center Copenhagen

  • Merete Nordentoft, MD, PhD, MPH · Psychiatric Center Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484302 on ClinicalTrials.gov